key: cord-0966844-80cbwj3o authors: XIANG, Y.; ZHANG, R.; QIU, J.; So, H.-C. title: Association of COVID-19 with risks of hospitalization and mortality from other disorders post-infection: A study of the UK Biobank date: 2022-03-23 journal: nan DOI: 10.1101/2022.03.23.22272811 sha: 632eb1dbd85390b88dd194c9adc611394eef96d8 doc_id: 966844 cord_uid: 80cbwj3o Background More than 0.4 billion cases of COVID-19 have been reported worldwide. The sequalae of COVID-19 remains unclear, especially whether it may be associated with increased hospitalization and mortality from other diseases. Methods We leveraged a large prospective cohort of the UK biobank (UKBB) (N=412,096; current age 50-87) to identify associations of COVID-19 with hospitalization and mortality due to different diseases post-infection. We conducted a comprehensive survey on disorders from all systems (up to 135 disease categories). Multivariable Cox and Poisson regression was conducted controlling for main confounders. For sensitivity analysis, we also conducted separate analysis for new-onset and recurrent cases, and other sensitivity analysis such as the prior event rate adjustment (PERR) approach to minimize effects of unmeasured confounders. Results Compared to individuals with no known history of COVID-19, those with severe COVID-19 (requiring hospitalization) exhibited higher hazards of hospitalization and/or mortality due to multiple disorders (median follow-up=608 days), including disorders of respiratory, cardiovascular, neurological, gastrointestinal, genitourinary and musculoskeletal systems. Increased hazards of hospitalizations and/or mortality were also observed for injuries due to fractures, various infections and other non-specific symptoms. These results remained largely consistent after sensitivity analyses. Severe COVID-19 was also associated with increased all-cause mortality (HR=14.700, 95% CI: 13.835-15.619). Mild (non-hospitalized) COVID-19 was associated with modestly increased risk of all-cause mortality (HR=1.237, 95% CI 1.037-1.476) and mortality from neurocognitive disorders (HR=9.100, 95% CI: 5.590-14.816), as well as hospital admission from a few disorders such as aspiration pneumonitis, musculoskeletal pain and other general signs/symptoms. Conclusions In conclusion, this study revealed increased risk of hospitalization and mortality from a wide variety of pulmonary and extra-pulmonary diseases after COVID-19, especially for severe infections. Mild disease was also associated with increased all-cause mortality. Further studies are required to replicate our findings. There are more than 400 million 1 documented cases of COVID-19 worldwide, and accumulating evidence have shown that the disease may be associated with various sequelae. For example, respiratory symptoms and disorders were reported frequently in the post-infection period, such as dyspnoea and cough 2 , lung function impairment 3 , and bronchiectasis 4 . Relatively less attention has been paid on other organ systems. For example, studies have reported that neurological manifestations could persist in patient with COVID-19 [5] [6] [7] . Increased risks of cardiovascular diseases have also been observed 8 . Several other studies have also investigated the health consequences of COVID-19 across different systems [9] [10] [11] [12] . Nevertheless, the full spectrum of sequalae from COVID-19 remains unclear, and there are still limited studies which have conducted a comprehensive analysis on potential sequelae from all body systems. To define history of relevant diseases, we included information from primary care and hospital inpatient data, as well as ICD-10 diagnoses (code 41270) and self-reported illnesses (code 20002 Missing values of features were imputed with "missRanger". The program is based on missForest, an iterative imputation approach using random forest. The program has been widely used and has been shown to produce low imputation errors and good performance in predictive models 17 . The missing rate of each covariate and the OOB (out-of-bag error) of imputation are listed in Table S2 . "Severe" COVID-19 was defined by any case who is hospitalized or whose mortality is due to U07.1. Other non-hospitalized and non-fatal cases are considered as 'mild'. For hospitalized cases, we required both test result and test origin to be 1 (positive test and inpatient origin). For a small number of cases with initial outpatient origin and positive test result, but changed to inpatient origin within 2 weeks, we still considered these subjects as inpatient cases (i.e., we shall assume the hospitalization was related to . Four sets of analysis were performed for hospitalization and mortality as outcome separately (Table 1) . For model A, it was restricted to test-positive subjects, while for other models, they were based on the whole population. For Model A, we compared severe vs mild COVID-19 cases for post-infection hospital admission and mortalities. For model B, we compared severe COVID-19 cases against those with no known history of infection. For model C, all infected cases were compared against those with no known infection. Finally, 'mild COVID-19' were compared against subjects with no known infection in model D. . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 23, 2022. ; https://doi.org/10.1101/2022.03.23.22272811 doi: medRxiv preprint Cox and Poisson regression were employed for analysis. Cox regression models time to development of event, while Poisson regression models the incidence rate (with consideration of follow-up time). Briefly, the time to hospitalization or mortality from the studied diseases was treated as outcome in Cox regression, controlling for other covariates. For Poisson regression, presence/absence of the event of interest was considered as outcome, with 'offset' specified (=number of days of follow-up) to account for the differences in duration of follow-up for each subject. For subjects with COVID-19 infection, the first positive date was treated as the start-date (time0) of this cohort study. For subjects free of COVID-19 infection, 31-Jan-2020 were assigned as time0. The end of follow-up was set as the time a participant developed an event of interest or 30 Sep 2021 (for analysis of hospitalization) or 18 Oct 2021 (for analysis of mortality). All statistical analysis were performed by R (version number 3.6.1). The false discovery rate (FDR) approach by Benjamini and Hochberg 18 was performed to control for multiple testing, which controls the expected proportion of false-positives in the rejected hypotheses. To avoid convergence issues when large number of predictors are included, we followed the methodology described by Zhao et al. 19 to further select covariates for inclusion. We first included several 'default' variables, including age, sex and general health status (number of hospitalization and medications received in the past year) into the regression model. For the rest of the covariates, univariate testing was performed with each predictor; those with nominally significant associations (p<0.05) with the outcome were selected into the final model. This approach 19 was shown by theory and simulations to control the proportion of false positive predictors. Prior event rate ratio (PERR) adjustment Although many possible confounders have been adjusted for, the chance of residual confounding remains. The PERR approach exploits a before-and-after design to minimize the effects of unmeasured confounders [20] [21] [22] . The basic idea is to compare the differences in hazard ratios between the exposed and unexposed groups before and after the COVID-19 pandemic, as differences in hospitalization/mortality risks prior to the pandemic can be due to baseline differences (unmeasured confounders) between the two groups. We may assume that before the onset of the pandemic in UK (31 Jan 2020), the hazard ratio of event (e.g. hospitalization due to a specific disease) between the exposed and unexposed groups is HRbefore. Since neither group would have COVID-19 before our study baseline, HRbefore is assumed to reflect baseline differences owing to unmeasured confounders, independent of the effect of COVID-19. Similarly, we define the differences between groups after the pandemic onset to be HRafter. The PERR-adjusted HR, calculated as HRafter/HRbefore, provides an estimate of the effect of COVID-19 infection accounting for both unmeasured and measured confounders. The evaluation of HRafter/HRbefore is equivalent to evaluating the difference in regression coefficients before and after treatment, i.e. betadiff = betaafter-betabefore. A non-parametric bootstrap procedure (re-sampling observations with replacement) was used to estimate the standard error (SE) of betadiff 22 . The z-statistic can then be computed by betadiff/SE(betadiff). We performed further PERR adjustment for all significant associations (unadjusted p-value<0.05) in the original analysis. Two hundred bootstraps were performed. The PERR approach have several assumptions. It is assumed that the confounders (measured and unmeasured) have the same effect in both pre-and post-COVID-19 periods. Also, the probability of (severe) COVID-19 infection is assumed to be unaffected by events (hospitalization due to diseases) in the prior period. In this cohort study, the start-date (time0) for the exposed group is the first date of being tested positive, while an artificial time0 was assigned to the unexposed group. Imbalance of 'prescription time' (here 'prescription' refers to being infected by COVID-19) distribution may lead to a typical bias known as 'survival bias'. Survival bias may be generated when individuals who die shortly after the start of follow-up might not have a probability of being infected and would only be classified into the 'unexposed group' by definition. As a result, events in the unexposed group may be over-estimated, and this bias is likely more prominent for the study of mortalities (or hospitalizations due to a lethal disease, e.g. stroke). To reduce such bias, several methods have been proposed (see 23 ). Here we employed the PTDM approach as it is computationally fast and has been shown to effectively reduce survival bias 23 . In brief, for each person without COVID-19 infection, instead of using the same start-date (31 Jan 2020), an alternative time0 was generated by randomly choosing from the sets of time0 of the COVID-19-exposed group. Subjects who are unaffected by COVID-19 but had an event before the assigned time0 are excluded from the analysis. The objective is to ensure a similar distribution of the time0 across both groups. Note that in this study, we may expect more associations of COVID-19 with sequelae after PTDM adjustment, as under PTDM time0 is pushed to a later date for the unexposed group and fewer events (or lower incidence rate) would be observed in that group. Other analysis to check for robustness of findings is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint We performed a variety of different analyses to verify the robustness of our findings under different modeling strategies and assumptions: (1) While we primarily focused on all hospitalizations, we also performed stratified analysis for new-onset and recurrent diseases, as mentioned earlier; (2) for counting the follow-up end date, we primarily consider the last date of available hospitalization/mortality records as the end of follow-up. However, since vaccination may change the risk of sequelae, we also performed our analysis limited to the period when no vaccines were yet available, i.e. setting 8 Dec 2020 (the date of first vaccination) as our study end-date; Association with hospital admission/mortality stratified by vaccination status and follow-up period We also conducted further (exploratory) analysis stratified by vaccination status. Briefly, we compared hospitalization rates for subjects who have received at least one dose of vaccine before infection, those who have received vaccine after the infection, those who are vaccinated both before and after the infection, those who are infected but not vaccinated and those with no known COVID-19. One of our main questions is whether prior vaccination (and to a lesser extent, vaccination after infection) may ameliorate the risk of sequelae, when compared to infected subjects who are not vaccinated. In another additional analysis, we examined the effect of COVID-19 on hospitalization risks as stratified by the follow-up period. Three periods were specified, namely <3 months, 3-6 months and >6 months. We hypothesized that the risk would be most prominent in the initial months and might wane afterwards. In this study, we found that severe COVID-19 was associated with elevated hazards ratios (HR) of hospital admission and mortality due to various diseases involving many body systems. These patterns were consistent in a series of sensitivity analyses, and after PTDM and PERR adjustment. The four sets of analysis are summarized in Table 1 and the number of subjects for each model is presented in Table 2 . Compared to subjects with no known history of COVID-19, association of hospitalization with severe COVID- Severe infection was associated with higher hazards of hospitalization and mortality due to a broad array of diseases (median follow-up = 608 days). The main results are listed in Table 3 and full results in Table S3 . Here we primarily present the results based on Cox regression model, without further adjustments by PTDM or PERR. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint When we restricted the outcome to hospitalization from new-onset or recurrent diseases, most of our results were similar. Higher risks of hospitalization from a few additional disorders were found when we performed analysis on hospitalizations from new-onset diseases, including coronary atherosclerosis and other heart diseases . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 23, 2022. We also repeated the analysis using Poisson regression which models the incidence rate of hospitalization. The results were similar to those from Cox regression, with similar significant associations observed (Table S3) . Compared to subjects with mild COVID-19, association of hospitalization with severe COVID-19 (severe vs mild infection) Here we compared the risk of hospitalization of severe vs mild cases within the infected individuals (Table 4) . (1.921-6.644); p.adj= 4.66e-04). We also observed increased risk of hospitalization from several digestive disorders, infectious conditions, injury and general signs/symptoms, which are listed in Table 4 . Compared to subjects with no known history of COVID-19, association of hospitalization with mild COVID- We found from this analysis (model D) that history of 'mild' (i.e. non-hospitalized) COVID-19 were associated increased hazards of hospital admission due to musculoskeletal pain (excluding low back pain) (HR=1.937 p.adj= 6.59e-04), as shown in Table S3 . Higher hazards of all-cause mortality (1.237 (1.037-1.476); p.adj=2.27e-02) and mortality due to neurocognitive disorders (9.100 (5.590-14.816); p.adj=7.33e-18) were also observed. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 23, 2022. ; https://doi.org/10.1101/2022.03.23.22272811 doi: medRxiv preprint Compared with subjects with no known history of COVID-19, association of hospitalization with any COVID- The results from this analysis (model C) were largely similar to those from model B. Details can be found in Table S3 . In addition to findings from model B, we also found increased hazards of hospitalization from essential hypertension (3.061 (1.397-6.705); p.adj=2.09e-02), obesity ( is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The primary results with PERR adjustment (with prior exposure period restricted to 30-Jan-2018 to 30-Jan-2020) are listed in Table 5 . With the PERR adjustment, compared to those with no known history of COVID-19, severe COVID-19 was significantly associated with increased hazards of hospital admission due to pulmonary disorders, like pneumonia (except that caused by tuberculosis) ( We note that the PERR adjustment tends to be conservative in general in our case. By the assumptions of PERR, the prior events should have no effect on the risk of exposure 21 ; however here the history of many diseases could increase the risk of (severe) COVID-19 infection. As a result, the hazard ratio of hospitalization (for infected vs non-infected groups) will be higher than expected even in the pre-COVID-19 period, since the (severely) infected group are more likely to be hospitalized for diseases even in the pre-COVID period. This will lead to a conservative bias, as also shown in previous simulation studies 21 . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The primary results of associations with mortality after COVID-19 (without PTDM adjustment) are listed in Table 6 and full results in Table S4 . We found that severe COVID-19 was associated with increased all-cause mortality (HR=14.700 (13.835-15.619); p.adj<9.6e-231); significantly increased risk of mortality was also observed for mild disease, albeit with an attenuated effect size (1.237 (1.037-1.476); p.adj= 2.27e-02). Considering cause-specific mortality (without considering the past history of disease), severe infection was associated with mortality due to pneumonia (except that caused by tuberculosis) Table 6 ). Associations with mortality after any infection (model C) are largely similar. When we only considered fatalities from those with a history of the disease, most associations were non-significant, likely due to the small number of events and lower statistical power. Associations with mortality with PTDM adjustment is similar to those without PTDM adjustment (Table S4) . Association of all hospitalization/mortality after COVID-19 before the launch of vaccination (i.e. prior to 8 Dec 2020) are presented in Tables S5 and S6. The spectrum of sequelae remained similar. As for mortality, increased hazards of all-cause mortality and mortality due to specific common causes such as coronary atherosclerosis and other heart disease, acute hemorrhagic cerebrovascular disease, COPD, and other cancers were also observed when the analysis was limited to the 'pre-vaccination' period. The associations with sequelae stratified by vaccination status are presented in Table S7 . We will focus on the comparison between subjects with vaccination before (and to a lesser extent, after) the infection against those infected but have not received any vaccination. A few results were nominally significant. For the analysis on breakthrough infections vs infection without vaccination, we observed lower risks of hospitalization from pneumonia, unspecified lower respiratory diseases and other general signs/symptoms from the former group. We observed increased rates of hospitalization from a few non-specific causes, including low back pain, non-specific chest pain and cataracts. However, such results may not be straightforward to interpret as the exact reason for admission is known (e.g. admission could be for an elective operation). The findings should be considered is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 23, 2022. ; https://doi.org/10.1101/2022.03.23.22272811 doi: medRxiv preprint tentative as most of the above findings are marginally significant except for general signs and symptoms (p=1.83e-15). We then compared those vaccinated after infection against those infected and unvaccinated. The former group had lower hazards of hospitalization from injuries, pneumonia, bacterial infections, septicaemia and other general signs and symptoms, under the original model without PTDM adjustment. Nevertheless, for subjects who received vaccinations after being infected, we only consider events occurring after vaccination, when comparing with infected but unvaccinated subjects (for whom we will consider all events after infection). As such, the PTDM adjustment may produce more reasonable results. No results were nominally significant under PTDM except for urinary tract infections which was marginally significant. As for the analysis stratified by follow-up period, we observed larger effects from COVID-19 infection and more statistically significant associations when restricting analysis of outcome to the first 3 months, and in general the effects of infection attenuated over time (Table S8) . Nevertheless, it is noteworthy that even after 6 months, infections or severe infections in particular, were still associated with elevated hospitalization risks from numerous conditions. These conditions included, for example, aspiration pneumonitis, acute renal failure, injuries and fractures, and various infections such as urinary tract infections, septicaemia, pneumonia and other bacterial infections (Table S8) . Overall, we found that COVID-19, especially severe disease, were associated with increased risks of hospitalization and/or mortality due to pulmonary, cardiovascular, digestive, neurological, genitourinary and musculoskeletal disorders in the post-infection period. These results were largely consistent and robust to multiple sensitivity analysis, and after PERR and PTDM adjustment. We noted that a recent study by Al-Aly et al. has characterized the post-acute sequelae of COVID-19 in US veterans 9 for a range of outcomes, however the study was on veterans only which may affect its generalizability to the general population and females. The focus of Al-Aly et al. was also somewhat different from ours, as they focused on incident (new) diagnoses post-infection, while we studied hospitalization due to new or recurrent diseases. As such, a person with history of a disorder (e.g. stroke) who was admitted for the same disease post- is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 23, 2022. ; https://doi.org/10.1101/2022.03.23.22272811 doi: medRxiv preprint infection will be considered by our study but not in Al-Aly et al. We also studied mortality due to all disorders covering all systems. In this study we utilized a large prospective cohort of UKBB to delineate the septum of hospital admission and mortality cause up to 20 months after COVID-19. We have conducted a very comprehensive set of analyses, which includes all hospitalization and mortality from diseases covering all systems, as well as stratified analysis on new-onset and recurrent diseases. We also performed other sensitivity analyses such as PTDM and PEER adjustments. The PEER adjustment for example can help to reduce residual confounding and help evaluate causal relationships between COVID-19 and possible sequelae, which has not been employed in the above study 9 . A number of studies have been performed on the longer-term sequelae of COVID-19 (mostly focused on specific organ systems), and have revealed elevated risks for a variety of disorders, which corroborate with our findings in general. For example, impaired lung function and respiratory conditions are among the most commonly reported sequelae of COVID-19 3, 4 . Two previous studies on US veterans 8, 9 have revealed that COVID-19 was associated with a wide range of cardiovascular disorders including dysrhythmias, inflammatory and ischemic heart diseases, thrombotic disorders, heart failure, cerebrovascular conditions and others. The current study also revealed a similar spectrum of cardiovascular in a general population cohort based on an independent sample. Cerebrovascular disorders were also commonly reported as complications of COVID-19, as reviewed elsewhere 31, 32 . Also, renal involvement is not uncommon during the acute phase of infection, and subclinical inflammation may persist for many months 33, 34 . Deterioration of renal function following acute infection has been reported 11 . Although the mechanisms remain poorly understood, neurocognitive impairment was observed for patients after recovery from COVID-19 [35] [36] [37] . In a large-scale retrospective cohort study 38 , it was reported that the incidence of most neurological and psychiatric disorders were raised after COVID-19, compared to those with influenza or other respiratory tract infections, especially for the most severe COVID-19 cases requiring intensive care support. We also observed that COVID-19 patients were more likely to be admitted for other bacterial or viral infections post-infection. Elevated risk of hospitalization was not only observed for pneumonia, but also other infective conditions such as septicemia, peritonitis and intra-abdominal abscess, intestinal infection, urinary tract infections (UTI), osteomyelitis, and other bacterial infections. The exact mechanisms remain unclear, however for postinfluenza infections, it has been suggested that secondary infections could be due to disruption of airway epithelium owing to immune-mediated damage and dysfunctional innate immune responses 39, 40 . Since corticosteroids are often prescribed for severe COVID-19 infections, it may be worthwhile to investigate whether steroid use is associated with increased risks of other infections 41 . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Another interesting finding is that we observed increased risk of hospitalization from several musculoskeletal problems, especially fractures. Increased risks of fall may be one important contributing factor, which in turn could be due to myriad reasons such as malaise and fatigue, musculoskeletal pain, muscle weakness, neurocognitive impairment, poor general well-being and the increased incidence of other disorders that may increase fall risk post-infection 9, 42 . Another contributing factor may be increased risks of osteoporosis due to COVID-19 itself 43 and/or its treatment (e.g. steroids), but further clinical studies are required. We also noted increased risks of hospitalization from several neoplasms, which may be due to, for example, deconditioning and increased risk of secondary infections after the acute COVID-19 infection, given that it is unlikely that COVID-19 would affect the incidence of neoplasms. While this is an observational study, it is interesting to note that Mendelian randomization studies, which are less prone to confounding, have also shown that COVID-19 may be a causal risk factor for various cardiometabolic and neuropsychiatric disorders 44, 45 . The mechanisms underlying COVID-19 sequelae are still largely unknown, and different symptoms/disorders may also involve different pathophysiologies. It has been postulated that, for example, persistent reservoirs of the virus, on-going inflammation, dysregulated immune response and re-activation of pathogens may all contribute to the long-term sequelae 46, 47 . Our findings may have important clinical implications. We observed that COVID-19, especially severe infections requiring hospitalization, is associated with a wide variety of pulmonary and extra-pulmonary sequelae. Alarmingly, elevated risk of admission and mortality was observed for multiple disorders spanning many organ systems. Patients who have recovered from especially severe COVID-19 may therefore require appropriate follow-up, monitoring and risk assessment for different complications. It remains to be investigated what types of interventions may help to reduce the risk of sequelae. From a public health perspective, when determining policies related to the pandemic (such as lifting restrictions), one should consider the total burden caused by COVID-19 that includes its possible complications, and the disabilities and mortalities due to these complications. Our findings also call for allocation of resources to prevent and treat the relevant complications. Another alarming finding is that even mild (non-hospitalized) COVID-19 is associated with modestly increased risk of all-cause mortality (HR=1.237, 95% CI 1.037-1.476) and mortality from neurocognitive disorders (HR= 9.100, 95% CI: 5.590-14.816 ), as well as hospital admission from a few disorders such as aspiration pneumonitis, is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 23, 2022. ; https://doi.org/10.1101/2022.03.23.22272811 doi: medRxiv preprint musculoskeletal pain and other general signs/symptoms. Such findings are in line with previous studies 31, 32 which also showed elevated risks of cardiovascular and other sequelae even for mild COVID-19 cases. Given the huge number of people infected by COVID-19, even a modest rise in the hazard for mortality would imply a large (absolute) number of fatalities. This suggests containment of infection is still important together with efforts to reduce the number of severe cases. The major strength of this study included large sample size of the UK Biobank with detailed health records and sufficient period of follow-up. This study is very comprehensive and covers most clinically relevant categories of diagnosis. In addition to any hospitalization/mortality, we also performed additional analysis on hospitalization with/without relevant history of disease (i.e. new-onset and recurrent diseases). Apart from these, we also made use of advanced statistical methods to evaluate whether our findings are consistent to different modeling strategies. For example, the PERR adjustment was employed to minimize unmeasured confounding. There are several limitations of this study. Firstly, this is an observational study. Although we have included many known confounders in the model and used other methods (e.g. PERR) to minimize residual confounding, confounding effects cannot be excluded completely. However, many results remained significant after PERR adjustment which provides further support to our findings. Secondly, subclinical disorders may be underestimated and some disorders may be too rare to be included for further analysis. In addition, due to the relatively small number of events for some disorders, absence of significant associations can also be due to inadequate statistical power. We also note that mild or asymptomatic infections may not be detected and considered as having no history of COVID-19; however this is likely to result in a conservative bias. Variant information is not known and thus cannot be analyzed, although we expect the alpha and delta variants are likely the predominant variants. Further studies are required to investigate the sequelae from other variants, such as Omicron. Finally, UKBB participants are likely healthier and of higher socioeconomic status 48 , and generalizability of current findings to other populations (e.g. other ethnicities and those aged<50) may require further studies. In conclusion, this study revealed increased risk of hospitalization and mortality from a wide variety of pulmonary and extra-pulmonary diseases after COVID-19, especially for those with severe disease. On the other hand, we also observed increased all-cause mortality and mortality due to neurocognitive disorders after mild infections. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint An interactive web-based dashboard to track COVID-19 in real time A clinical review of long-COVID with a focus on the respiratory system Respiratory function in patients post-infection by COVID-19: a systematic review and metaanalysis Post COVID-19 bronchiectasis: a potential epidemic within a pandemic Long-Term Respiratory and Neurological Sequelae of COVID-19 A Contemporary Review of Neurological Sequelae of COVID-19 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records Long-term cardiovascular outcomes of COVID-19 High-dimensional characterization of post-acute sequelae of COVID-19 Post-acute COVID-19 syndrome 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study Persistent symptoms in patients after acute COVID-19 Are Patients at Veterans Affairs Medical Centers Sicker?: A Comparative Analysis of Health Status and Medical Resource Use Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age Utilization Project (HCUP) Agency for healthcare research and quality Comparison of imputation methods for missing laboratory data in medicine Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing Principled sure independence screening for Cox models with ultra-high-dimensional covariates Prior event rate ratio adjustment produced estimates consistent with randomized trial: a diabetes case study Performance of prior event rate ratio adjustment method in pharmacoepidemiology: a simulation study Replication of the Scandinavian Simvastatin Survival Study using a primary care medical record database prompted exploration of a new method to address unmeasured confounding Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods Relevance of a standard measurement of undernutrition to the diagnosis of anorexia nervosa: Use of Quetelet's Body Mass Index (BMI) A clinical perspective of obesity, metabolic syndrome and cardiovascular disease Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults Variation of the hemoglobin level with age and sex The Difference between the Population Attributable Risk (PAR) and the Potentioal Impact Fraction (PIF) Neurological consequences of COVID-19: what have we learned and where do we go from here Neuroimaging findings of brain MRI and CT in patients with COVID-19: A systematic review and meta-analysis Long COVID and kidney disease COVID-19 Survival and its impact on chronic kidney disease COVID-19 and neurocognitive disorders Depressive and Neurocognitive Disorders in the Context of the Inflammatory Background of COVID-19 Frequent neurocognitive deficits after recovery from mild COVID-19 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records Immune dysfunction and bacterial coinfections following influenza The co-pathogenesis of influenza viruses with bacteria in the lung Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study UK Government urged to recognise post-COVID-19 cancer backlog Osteoclast-mediated bone loss observed in a COVID-19 mouse model Exploring causal relationships between COVID-19 and cardiometabolic disorders: A bi-directional Mendelian randomization study. medRxiv Neuropsychiatric disorders as risk factors and consequences of COVID-19: A Mendelian randomization study. medRxiv Pathological sequelae of long-haul COVID Long COVID: to investigate immunological mechanisms and sex/gender related aspects as fundamental steps for tailored therapy Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population All supplementary Tables and notes are available at the journal's website and at https://drive.google.com/drive/folders/1Mqy5Qfu8QSe1RAYgy11fcqkY0M-XzZtJ?usp=sharing The authors declare no conflict of interest.